1. Scrip
  2. >>Business

Stockwatch: Damage Not Controlled

 
• By Andy Smith

As financial turmoil broke out around the world in the wake of the vote for Brexit, UK pharma majors GlaxoSmithKline and AstraZeneca saw their stock rise. There's an uncertain outlook for the broader life sciences sector.

Brexit

I was unfortunately and publicly proved right about two events last week. Unfortunate, because neither was a positive outcome. On the Brexit vote, I was right partly for the wrong reason since I guessed that there was a certain stigma associated with responding to a pollster with an intent to vote to leave the EU. I thought that some respondents would say that they were undecided even if they had decided to vote to leave and therefore the polls would underestimate the leave vote.

Whilst all of us in the UK now have to live with that stigma, there will be long-term financial implications...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

 
• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 
• By Jessica Merrill

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

More from Scrip

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By Manas Mishra

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

Viking Rapidly Advancing Oral And Injectable VK2735 For Obesity

 
• By Joseph Haas

In its Q2 update, Viking reported that Phase III trials of subcutaneous VK2735 are under way, and that it expects Phase II data for an oral formulation before year’s end.

Rocket Comes Back To Earth With Restructuring Plan

 
• By Alaric DeArment

The biotech will lay off nearly one-third of its workforce and focus on its cardiovascular gene therapy programs.